Table 3.

Drug resistance mutations emerging after incarceration in the ALIVE cohort

Drug class	Mutation	Sample #(s) (% frequency)
Protease inhibitors	L10IFVC	19 (7.9%)
	V11I	25 (6.0%)
	G16E	25 (3.2%)
	K20RMITV	24 (7.0%)
	M36LIV	24 (5.5%)
	M46IL	27 (7.3%)
	F53LY	16 (5.1%)
	I62V	4 (15.3%)
	I64LMV	4 (13.7%)
	G73CSTA	6 (8.1%)
	V77I	13 (4.6%)
	L89VIM	22 (3.6%)
	L90M	6 (16.2%)
NRTI inhibitors	M41L	2 (13.3%)
	A62V	2 (3.1%)
	M184V	2 (99.9%), 5 (82.8%), 9 (99.8%), 10 (100%), 16 (56.6%), 23 (68.5%)
NNRTI inhibitors	K103N	5 (100%), 10 (100%), 23 (99.8%)
	V108I	23 (59.8%)
	E138KAGQR	16 (7.6%)
	P225H	23 (55.3%), 10 (99.9%)
Integrase inhibitors	S147G	16 (7.6%)

Boldface font = major mutation. Regular font = accessory mutation.